Olsalazine | hsa00190 | Oxidative phosphorylation | 2.21E-02 | 3 | Q16718, Q13488, O14521 | NDUFA5, TCIRG1, SDHD | More | |
Olsalazine | hsa00280 | Valine, leucine and isoleucine degradation | 1.63E-04 | 4 | P55809, Q9HCC0, Q02252, P11310 | OXCT1, MCCC2, ALDH6A1, ACADM | More | |
Olsalazine | hsa00561 | Glycerolipid metabolism | 2.21E-02 | 3 | O14494, P06280, P23743 | PLPP1, GLA, DGKA | More | |
Olsalazine | hsa00600 | Sphingolipid metabolism | 3.96E-02 | 3 | Q9BX95, O14494, P06280 | SGPP1, PLPP1, GLA | More | |
Olsalazine | hsa03013 | RNA transport | 4.13E-02 | 6 | Q09161, P35658, P47813, Q14152, O75822, P51114 | NCBP1, NUP214, EIF1AX, EIF3A, EIF3J, FXR1 | More | |
Olsalazine | hsa04064 | NF-kappa B signaling pathway | 4.09E-03 | 8 | P10415, O00463, Q04759, Q9UDY8, Q16548, Q13315, P24522, P09341 | BCL2, TRAF5, PRKCQ, MALT1, BCL2A1, ATM, GADD45A, CXCL1 | More | |
Olsalazine | hsa04071 | Sphingolipid signaling pathway | 1.19E-02 | 5 | P21453, Q9H228, Q13362, Q9BX95, P10415 | S1PR1, EDG8, PPP2R5C, SGPP1, BCL2 | More | |
Olsalazine | hsa04080 | Neuroactive ligand-receptor interaction | 1.00E-02 | 7 | P08311, Q15722, P21453, Q9H228, O00398, P21730, P07550 | CTSG, LTB4R, S1PR1, EDG8, P2RY10, C5AR1, ADRB2 | More | |
Olsalazine | hsa04140 | Autophagy - animal | 3.19E-02 | 4 | P22694, Q14643, P10415, Q04759 | PRKACB, ITPR1, BCL2, PRKCQ | More | |
Olsalazine | hsa04145 | Phagosome | 4.79E-03 | 10 | P60709, Q15075, Q15080, P14598, Q13509, Q13488, P05164, O60603, P35443, P13765 | ACTB, EEA1, NCF4, NCF1, TUBB3, TCIRG1, MPO, TLR2, THBS4, HLA-DOB | More | |
Olsalazine | hsa04210 | Apoptosis | 3.44E-02 | 7 | Q13315, P10415, O76075, P24522, Q16548, P43234, Q14643 | ATM, BCL2, DFFB, GADD45A, BCL2A1, CTSO, ITPR1 | More | |
Olsalazine | hsa04340 | Hedgehog signaling pathway | 3.09E-02 | 3 | P22694, Q13635, P10415 | PRKACB, PTCH1, BCL2 | More | |
Olsalazine | hsa04612 | Antigen processing and presentation | 4.48E-02 | 5 | P13765, P26715, P26717, Q13241, P01732 | HLA-DOB, KLRC1, KLRC2, KLRD1, CD8A | More | |
Olsalazine | hsa04613 | Neutrophil extracellular trap formation | 4.93E-02 | 8 | O60603, P05164, P08246, Q9UM07, Q15080, P20160, P08311, P21730 | TLR2, MPO, ELA2, PADI4, NCF4, AZU1, CTSG, C5AR1 | More | |
Olsalazine | hsa04650 | Natural killer cell mediated cytotoxicity | 2.96E-02 | 6 | O60880, P20963, Q13241, P26718, P26717, P26715 | SH2D1A, CD247, KLRD1, KLRK1, KLRC2, KLRC1 | More | |
Olsalazine | hsa04658 | Th1 and Th2 cell differentiation | 1.07E-03 | 7 | Q04759, P20963, P09693, Q14765, P23771, Q9UL17, P13765 | PRKCQ, CD247, CD3G, STAT4, GATA3, TBX21, HLA-DOB | More | |
Olsalazine | hsa04659 | Th17 cell differentiation | 1.90E-02 | 6 | Q04759, P13765, Q9UL17, P23771, P09693, P20963 | PRKCQ, HLA-DOB, TBX21, GATA3, CD3G, CD247 | More | |
Olsalazine | hsa04660 | T cell receptor signaling pathway | 1.00E-02 | 7 | Q9UDY8, Q04759, P10747, Q08881, P20963, P09693, P01732 | MALT1, PRKCQ, CD28, ITK, CD247, CD3G, CD8A | More | |
Olsalazine | hsa04922 | Glucagon signaling pathway | 4.23E-02 | 4 | P22694, P06737, Q12778, Q14643 | PRKACB, PYGL, FOXO1, ITPR1 | More | |
Olsalazine | hsa04924 | Renin secretion | 1.04E-02 | 3 | P22694, P07550, Q14643 | PRKACB, ADRB2, ITPR1 | More | |
Olsalazine | hsa04928 | Parathyroid hormone synthesis, secretion and action | 4.23E-02 | 4 | Q14643, P22694, P23771, P10415 | ITPR1, PRKACB, GATA3, BCL2 | More | |
Olsalazine | hsa05110 | Vibrio cholerae infection | 4.50E-03 | 4 | Q13488, P17252, P19174, P60709 | TCIRG1, PRKCA, PLCG1, ACTB | More | |
Olsalazine | hsa05140 | Leishmaniasis | 4.75E-02 | 5 | P14598, P42224, P25963, P29350, Q15080 | NCF1, STAT1, NFKBIA, PTPN6, NCF4 | More | |
Olsalazine | hsa05150 | Staphylococcus aureus infection | 2.44E-02 | 4 | P21462, Q14532, P59665, P59666 | FPR1, KRT32, DEFA1; DEFA1B, DEFA3 | More | |
Olsalazine | hsa05202 | Transcriptional misregulation in cancer | 2.90E-02 | 9 | Q12778, Q13315, P14780, Q16548, O15550, P05164, P08246, Q9C0K0, P24522 | FOXO1, ATM, MMP9, BCL2A1, UTX, MPO, ELA2, BCL11B, GADD45A | More | |
Olsalazine | hsa05223 | Non-small cell lung cancer | 3.99E-02 | 4 | P17252, O43524, P19174, O75293 | PRKCA, FOXO3, PLCG1, GADD45B | More | |
Olsalazine | hsa05231 | Choline metabolism in cancer | 3.99E-02 | 4 | P19174, P23743, O14494, P17252 | PLCG1, DGKA, PLPP1, PRKCA | More | |
Olsalazine | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 2.84E-02 | 5 | P20963, P09693, O60603, P10747, Q04759 | CD247, CD3G, TLR2, CD28, PRKCQ | More | |
Olsalazine | hsa05321 | Inflammatory bowel disease | 1.17E-03 | 5 | O60603, P13765, Q14765, Q9UL17, P23771 | TLR2, HLA-DOB, STAT4, TBX21, GATA3 | More | |
Olsalazine | hsa05323 | Rheumatoid arthritis | 1.60E-02 | 4 | P13765, P10747, P09341, O60603 | HLA-DOB, CD28, CXCL1, TLR2 | More | |
Olsalazine | hsa05332 | Graft-versus-host disease | 3.45E-03 | 4 | P13765, P10747, P26715, Q13241 | HLA-DOB, CD28, KLRC1, KLRD1 | More | |
Olsalazine | hsa05415 | Diabetic cardiomyopathy | 3.94E-02 | 6 | P17252, P14598, Q15080, Q16718, O14521, P04406 | PRKCA, NCF1, NCF4, NDUFA5, SDHD, GAPDH | More | |